Erratum

Erratum to “Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis”

Max Borgström,¹ Mats Fredrikson,² Magnus Vrethem,¹ Pierfrancesco Mirabelli,³ Hans Link,⁴ and Yumin Huang-Link ¹

¹Division of Neurology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
²Department of Biomedical and Clinical Sciences and Forum Östergötland, Linköping University, Linköping, Sweden
³Division of Ophthalmology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
⁴Department of Clinical Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden

Correspondence should be addressed to Yumin Huang-Link; yumin.link@gmail.com

Received 24 June 2023; Accepted 24 June 2023; Published 12 October 2023

In the article titled “Changes in Retinal Thickness and Brain Volume during 6.8-Year Escalating Therapy for Multiple Sclerosis” [1], incorrect versions of Figures 1(a) and 1(b) were published due to an error in the production process. Specifically, “baseline” and “high-efficacy DMT” on the x-axis are incorrectly labelled. In addition, the x-axis labels are displaced from the corresponding bar chart columns. The correct figures are shown below.
Figure 1: Changes of GCIPL and pRNFL thickness over time. Bar charts represent the individual GCIPL (a) and pRNFL (b) from best eye of each patient during three different time points. The thickness of GCIPL was significantly thinner during 1st-line DMT ($p < 0.01$) and high-efficacy DMT ($p < 0.05$) compared to baseline. There are no significant differences of pRNFL thickness among the three different time points. DMT: disease-modifying treatment; GCIPL: ganglion cell inner-plexiform layer; pRNFL: peripapillary retinal nerve fibre layer.

References